Zoledronic Acid Treatment at Home: Safety Data from an Observational Prospective Trial

Tassinari, Davide; Poggi, B.; Nicoletti, S.; Fantini, Manuela; Tamburini, Emiliano; Possenti, C.; Sartori, Sergio

doi:10.1089/jpm.2006.0122

Cited by 23 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only one case of the use of bisphosphonates for bone metastasis of thyroid carcinoma has been reported. 39) Administration of zoledronic acid and alendronate sodium hydrate decreased uNTX in our Case 2, which indicated the suppression of bone resorption. Such suppression of bone resorption by bisphosphonates may be beneficial for patients with skull base metastasis of FTC.…”

Section: Discussionsupporting

confidence: 52%

Skull Base Metastasis From Follicular Thyroid Carcinoma -Two Case Reports-

Matsuno

Katakami

Okazaki

et al. 2010

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

A 58-year-old woman and a 71-year-old woman presented with extremely rare skull base metastases from follicular thyroid carcinoma (FTC). Surgical removal and external radiotherapy were performed followed by iodine-131 ( 131 I) brachytherapy and thyroid hormone administration. The metastatic tumors in the skull base were well controlled. Treatment for skull base metastasis from FTC includes surgical debulking of the metastatic lesion, as well as complete resection of the thyroid gland, followed by internal irradiation with 131 I, external irradiation, and administration of thyroid hormone to prevent tumor growth by suppression of endogenous thyroid-stimulating hormone. Skull base metastases may be the initial clinical presentation of FTC, with silent primary sites. The possibility of skull base metastasis from FTC should be considered in patients with clinical symptoms of cranial nerve dysfunction and radiological findings of bone destruction.

show abstract

Section: Discussionsupporting

confidence: 52%

Skull Base Metastasis From Follicular Thyroid Carcinoma -Two Case Reports-

Matsuno

Katakami

Okazaki

et al. 2010

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

show abstract

“…The use of bisphosphonates for bone metastasis of thyroid carcinoma has been reported in only 2 patients [39, 67]. Administration of zoledronic acid and alendronate sodium hydrate decreased urinary type I collagen N-telopeptide, which indicated the suppression of bone resorption.…”

Section: Treatment Of Skull Base Metastasis From Ftc and Ptcmentioning

confidence: 99%

Clinicopathological and Molecular Histochemical Review of Skull Base Metastasis from Differentiated Thyroid Carcinoma

Matsuno

Murakami

Hoya

et al. 2013

Acta Histochem. Cytochem

View full text Add to dashboard Cite

Skull base metastasis from differentiated thyroid carcinoma including follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC) is a rare clinical entity. Eighteen FTC cases and 10 PTC cases showing skull base metastasis have been reported. The most common symptom of skull base metastasis from FTC and PTC is cranial nerve dysfunction. Bone destruction and local invasion to the surrounding soft tissues are common on radiological imaging. Skull base metastases can be the initial clinical presentation of FTC and PTC in the presence of silent primary sites. The possibility of skull base metastasis from FTC and PTC should be considered in patients with the clinical symptoms of cranial nerve dysfunction and radiological findings of bone destruction. A variety of genetic alterations in thyroid tumors have been identified to have a fundamental role in their tumorigenesis. Molecular histochemical studies are useful for elucidating the histopathological features of thyroid carcinoma. Recent molecular findings may provide novel molecular-based treatment strategies for thyroid carcinoma.

show abstract

“…Occasionally, renal impairment due to NSAIDs and/or zoledronic acid commonly used at the terminal stage of cancer may occur. 23,24) Among opioids, particularly morphine and morphine-6-glucuronide are likely to be used at overdoses, possibly leading to the onset of respiratory depression. 25) European Association for Palliative Care and European Society for Medical Oncology guidelines recommend fentanyl as the first choice in patients with glomerular filtration rate (GFR) of less than 30 mL/min/1.73 m 2 .…”

Section: Discussionmentioning

confidence: 99%

A Clinical Study on Administration of Opioid Antagonists in Terminal Cancer Patients: 7 Patients Receiving Opioid Antagonists Following Opioids among 2443 Terminal Cancer Patients Receiving Opioids

Uekuzu

Higashiguchi

Futamura

et al. 2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

There have been few detailed reports on respiratory depression due to overdoses of opioids in terminal cancer patients. We investigated the situation of treatment with opioid antagonists for respiratory depression that occurred after administration of opioid at optimal doses in terminal cancer patients, to clarify pathological changes as well as causative factors. In 2443 terminal cancer patients receiving opioids, 7 patients (0.3%) received opioid antagonists: 6, morphine (hydrochloride, 5; sulfate, 1); 1, oxycodone. The median dosage of opioids was 13.3 mg/d, as converted to morphine injection. Respiratory depression occurred on this daily dose in 4 patients and after changed dose and route in 3 patients. Opioids were given through the vein in 6 patients and by the enteral route in 1 patient. Concomitant drugs included nonsteroidal anti-inflammatory drugs in 3 patients and zoledronic acid in 2 patients. In morphine-receiving patients, renal functions were significantly worsened at the time of administration of an opioid antagonist than the day before the start of opioid administration. These findings indicate that the proper use of opioids was safe and acceptable in almost all terminal cancer patients. In rare cases, however, a risk toward respiratory depression onset is indicated because morphine and morphine-6-glucuronide become relatively excessive owing to systemic debility due to disease progression, especially respiratory and renal dysfunctions. At the onset of respiratory depression, appropriate administration of an opioid antagonist mitigated the symptoms. Thereafter, opioid switching or continuous administration at reduced dosages of the same opioids prevented the occurrence of serious adverse events.

show abstract

Zoledronic Acid Treatment at Home: Safety Data from an Observational Prospective Trial

Abstract: The home treatment with zoledronic acid seems safe. The appropriate use of biphosphonates in such a new setting needs a criterion to identify the subset of patients with bone metastases confined to home who can really benefit by this treatment.

Cited by 23 publications

References 17 publications

Skull Base Metastasis From Follicular Thyroid Carcinoma -Two Case Reports-

Skull Base Metastasis From Follicular Thyroid Carcinoma -Two Case Reports-

Clinicopathological and Molecular Histochemical Review of Skull Base Metastasis from Differentiated Thyroid Carcinoma

A Clinical Study on Administration of Opioid Antagonists in Terminal Cancer Patients: 7 Patients Receiving Opioid Antagonists Following Opioids among 2443 Terminal Cancer Patients Receiving Opioids

Contact Info

Product

Resources

About